10-Q quarterly report · filed Nov 4, 2026

Personalis, Inc. (PSNL) Q3 2026 10-Q Quarterly Report

Short answer

Personalis, Inc. (PSNL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $26M (up 76.6% year over year) with net income of −$34M.

Q3 2026 key financials · XBRL

Revenue
$26M
+76.6% YoY · +14.5% QoQ
Net income
−$34M
−56.1% YoY · −6.7% QoQ
Operating margin
-138.8%
EPS (diluted)
−$0.31
−29.2% YoY · −3.3% QoQ

Source: XBRL data from the Personalis, Inc. (PSNL) Q3 2026 10-Q on SEC EDGAR. USD.

Personalis, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $25.6M, up 77% YoY from $14.5M, driven by pharma, clinical diagnostics and population sequencing
  • Operating margin -138.8% vs -160.7% YoY, calculated from operating losses of $35.5M and $23.3M
  • Best segment: clinical diagnostics $4.4M, up 1,039% YoY; worst: enterprise sales, down 99%
  • Cash and investments $190.6M vs $240.0M at year-end; nine-month operating cash use $75.3M
  • 2026 capital expenditures expected at $10.0M-$12.0M; headwinds include reimbursement-related testing costs and Merger uncertainty

Risk Factors

  • Pending Tempus merger, stockholder vote scheduled November 30, 2026, creates new completion and timing risk
  • Merger consideration, fixed exchange ratio 0.3356 below Tempus Floor Price $48.42, could value shares below $16.25
  • New tariff exposure, announced U.S. tariffs may raise laboratory costs that fixed-price contracts cannot immediately recover
  • Regulatory compliance, FDA could require medical-device authorization for LDTs, adding premarket review and ongoing obligations
  • Customer concentration, Moderna 13%, VA MVP 15%, and Merck 27% of nine-month 2026 revenue intensify renewal risk

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Personalis, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.